(Total Views: 580)
Posted On: 07/30/2019 3:15:17 PM
Post# of 15624
July has been a fairly exciting month for those few shareholders still paying attention to OWC; with one day to go:
OWC received approval from the Israeli Medical Cannabis Agency to perform an efficacy study using OWC's topical ointment on psoriatic patients.
The anxiously awaited Phase 1 tablet study was completed although there has been no official communication from the Company to Shareholders.
The share price of OWC's common stock trades at or near 52 week lows.
OWC received approval from the Israeli Medical Cannabis Agency to perform an efficacy study using OWC's topical ointment on psoriatic patients.
The anxiously awaited Phase 1 tablet study was completed although there has been no official communication from the Company to Shareholders.
The share price of OWC's common stock trades at or near 52 week lows.
(1)
(0)Scroll down for more posts ▼
